274 related articles for article (PubMed ID: 14573637)
1. Phage lytic enzyme Cpl-1 as a novel antimicrobial for pneumococcal bacteremia.
Loeffler JM; Djurkovic S; Fischetti VA
Infect Immun; 2003 Nov; 71(11):6199-204. PubMed ID: 14573637
[TBL] [Abstract][Full Text] [Related]
2. A novel chimeric phage lysin with high in vitro and in vivo bactericidal activity against Streptococcus pneumoniae.
Díez-Martínez R; De Paz HD; García-Fernández E; Bustamante N; Euler CW; Fischetti VA; Menendez M; García P
J Antimicrob Chemother; 2015; 70(6):1763-73. PubMed ID: 25733585
[TBL] [Abstract][Full Text] [Related]
3. Phage lytic enzymes as therapy for antibiotic-resistant Streptococcus pneumoniae infection in a murine sepsis model.
Jado I; López R; García E; Fenoll A; Casal J; García P;
J Antimicrob Chemother; 2003 Dec; 52(6):967-73. PubMed ID: 14613958
[TBL] [Abstract][Full Text] [Related]
4. Bactericidal synergism between daptomycin and the phage lysin Cpl-1 in a mouse model of pneumococcal bacteraemia.
Vouillamoz J; Entenza JM; Giddey M; Fischetti VA; Moreillon P; Resch G
Int J Antimicrob Agents; 2013 Nov; 42(5):416-21. PubMed ID: 23992647
[TBL] [Abstract][Full Text] [Related]
5. Bactericidal synergism between antibiotics and phage endolysin Cpl-711 to kill multidrug-resistant pneumococcus.
Letrado P; Corsini B; Díez-Martínez R; Bustamante N; Yuste JE; García P
Future Microbiol; 2018 Sep; 13(11):1215-1223. PubMed ID: 30238774
[TBL] [Abstract][Full Text] [Related]
6. In vitro interactions of LytA, the major pneumococcal autolysin, with two bacteriophage lytic enzymes (Cpl-1 and Pal), cefotaxime and moxifloxacin against antibiotic-susceptible and -resistant Streptococcus pneumoniae strains.
Rodríguez-Cerrato V; García P; Del Prado G; García E; Gracia M; Huelves L; Ponte C; López R; Soriano F
J Antimicrob Chemother; 2007 Nov; 60(5):1159-62. PubMed ID: 17827138
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy with Phage Lysins Reduces Pneumococcal Colonization of the Respiratory Tract.
Corsini B; Díez-Martínez R; Aguinagalde L; González-Camacho F; García-Fernández E; Letrado P; García P; Yuste J
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29581113
[TBL] [Abstract][Full Text] [Related]
8. Synergistic lethal effect of a combination of phage lytic enzymes with different activities on penicillin-sensitive and -resistant Streptococcus pneumoniae strains.
Loeffler JM; Fischetti VA
Antimicrob Agents Chemother; 2003 Jan; 47(1):375-7. PubMed ID: 12499217
[TBL] [Abstract][Full Text] [Related]
9. Pneumococcal LytA autolysin, a potent therapeutic agent in experimental peritonitis-sepsis caused by highly beta-lactam-resistant Streptococcus pneumoniae.
Rodríguez-Cerrato V; García P; Huelves L; García E; Del Prado G; Gracia M; Ponte C; López R; Soriano F
Antimicrob Agents Chemother; 2007 Sep; 51(9):3371-3. PubMed ID: 17576844
[TBL] [Abstract][Full Text] [Related]
10. ClyJ Is a Novel Pneumococcal Chimeric Lysin with a Cysteine- and Histidine-Dependent Amidohydrolase/Peptidase Catalytic Domain.
Yang H; Gong Y; Zhang H; Etobayeva I; Miernikiewicz P; Luo D; Li X; Zhang X; Dąbrowska K; Nelson DC; He J; Wei H
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30642930
[No Abstract] [Full Text] [Related]
11. Bacteremia with Streptococcus pneumoniae. Implications for therapy and prevention. Franklin County Pneumonia Study Group.
Plouffe JF; Breiman RF; Facklam RR
JAMA; 1996 Jan; 275(3):194-8. PubMed ID: 8604171
[TBL] [Abstract][Full Text] [Related]
12. Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase.
Loeffler JM; Nelson D; Fischetti VA
Science; 2001 Dec; 294(5549):2170-2. PubMed ID: 11739958
[TBL] [Abstract][Full Text] [Related]
13. Streptococcus pneumoniae bacteremia in southern Taiwan.
Lee CK; Liu JW; Leu HS; Jian C; Li CC
J Microbiol Immunol Infect; 2002 Mar; 35(1):17-22. PubMed ID: 11950115
[TBL] [Abstract][Full Text] [Related]
14. Bacteremic pneumococcal infections in immunocompromised patients without AIDS: the impact of beta-lactam resistance on mortality.
Fernández Guerrero ML; Ramos JM; Marrero J; Cuenca M; Fernández Roblas R; de Górgolas M
Int J Infect Dis; 2003 Mar; 7(1):46-52. PubMed ID: 12718810
[TBL] [Abstract][Full Text] [Related]
15. Improving the lethal effect of cpl-7, a pneumococcal phage lysozyme with broad bactericidal activity, by inverting the net charge of its cell wall-binding module.
Díez-Martínez R; de Paz HD; Bustamante N; García E; Menéndez M; García P
Antimicrob Agents Chemother; 2013 Nov; 57(11):5355-65. PubMed ID: 23959317
[TBL] [Abstract][Full Text] [Related]
16. SP-CHAP, an endolysin with enhanced activity against biofilm pneumococci and nasopharyngeal colonization.
Alreja AB; Appel AE; Zhu JC; Riley SP; Gonzalez-Juarbe N; Nelson DC
mBio; 2024 Apr; 15(4):e0006924. PubMed ID: 38470268
[TBL] [Abstract][Full Text] [Related]
17. Beta-lactam modification of the bacteraemic profile and its relationship with mortality in a pneumococcal mouse sepsis model.
Yuste J; Jado I; Fenoll A; Aguilar L; Giménez MJ; Casal J
J Antimicrob Chemother; 2002 Feb; 49(2):331-5. PubMed ID: 11815576
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcome of pneumococcal bacteremia, in vitro resistance, and antibiotic therapy.
Torres-Tortosa M; Caballero-Granado J; Canueto J; Moreno-Maqueda I
Clin Infect Dis; 2004 Mar; 38(5):763-4; author reply 765-6. PubMed ID: 14986265
[No Abstract] [Full Text] [Related]
19. Factors Associated With 30-Day Mortality Rate in Respiratory Infections Caused by Streptococcus pneumoniae.
Cheng MP; Bogoch II; Green K; Plevneshi A; Rudnick W; Shigayeva A; McGeer A; Lee TC;
Clin Infect Dis; 2018 Apr; 66(8):1282-1285. PubMed ID: 29140429
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic effects of bacteriophage Cpl-1 lysin against Streptococcus pneumoniae endocarditis in rats.
Entenza JM; Loeffler JM; Grandgirard D; Fischetti VA; Moreillon P
Antimicrob Agents Chemother; 2005 Nov; 49(11):4789-92. PubMed ID: 16251333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
